Kingdon Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Kingdon Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.18M	Buy	+1,352,106	New	+$1.88M	0.13%	65
2025 Q4	–	Sell	-1,324,845	Closed	-$3.15M	–	85
2025 Q3	$3.15M	Buy	1,324,845 +640,138	+93%	+$1.94M	0.39%	69
2025 Q2	$3.8M	Buy	684,707 +194,707	+40%	+$959K	0.51%	57
2025 Q1	$2.11M	Buy	490,000 +43,000	+10%	+$286K	0.22%	62
2024 Q4	$9.56M	Sell	447,000 -50,000	-10%	-$1.04M	1.36%	36
2024 Q3	$9.35M	Hold	497,000	–	–	1.04%	46
2024 Q2	$11.3M	Hold	497,000	–	–	1.21%	31
2024 Q1	$14.6M	Buy	497,000 +143,000	+40%	+$2.54M	1.59%	20
2023 Q4	$2.79M	Buy	354,000 +50,000	+16%	+$336K	0.35%	67
2023 Q3	$2.13M	Hold	304,000	–	–	0.25%	66
2023 Q2	$4.16M	Hold	304,000	–	–	0.39%	66
2023 Q1	$5.5M	Buy	304,000 +250,000	+463%	+$4.62M	1.03%	41
2022 Q4	$261K	Hold	54,000	–	–	0.05%	48
2022 Q3	$426K	Hold	54,000	–	–	0.05%	56
2022 Q2	$1.04M	Hold	54,000	–	–	0.18%	64
2022 Q1	$1.92M	Hold	54,000	–	–	0.2%	73
2021 Q4	$4.24M	Buy	+54,000	New	+$5.05M	0.49%	51

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Kingdon Capital Management's JSPR Position: Q1 2026 in Review

Kingdon Capital Management opened a new position in Jasper Therapeutics (JSPR) in Q1 2026: 1,352,106 shares worth $1.18M. The stake represents 0.13% of the portfolio and ranks #65 among its holdings. This is a return to the name: Kingdon Capital Management previously reported a position in JSPR as recently as Q3 2025.

Kingdon Capital Management first reported a position in JSPR in Q4 2021 and has held it in 17 quarters since. The position peaked at $14.6M in Q1 2024. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

Kingdon Capital Management held 1,352,106 shares of Jasper Therapeutics worth $1.18M as of Q1 2026.
Jasper Therapeutics was a new Kingdon Capital Management position in Q1 2026.
Jasper Therapeutics made up 0.13% of Kingdon Capital Management's portfolio in Q1 2026, its #65 holding.
Kingdon Capital Management first reported a position in Jasper Therapeutics in Q4 2021 and has held it in 17 quarters since.
Kingdon Capital Management's Jasper Therapeutics position peaked at $14.6M in Q1 2024.
58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Kingdon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.